Spira Alexander, Waters Dexter, Ran Tao, Vadagam Pratyusha, He Jinghua, Vanderpoel Julie, Donnelly Anjali, Lin Iris
Virginia Cancer Specialists, Fairfax, VA, United States; US Oncology Research, The Woodlands, TX, United States.
Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA, United States.
Cancer Treat Res Commun. 2025;44:100944. doi: 10.1016/j.ctarc.2025.100944. Epub 2025 May 15.
To describe characteristics, treatment patterns, and outcomes of patients with EGFR exon 20 insertion (exon20ins)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy (PBC).
This retrospective longitudinal cohort study pooled electronic health records from the Flatiron Health (January 2011-August 2022), Ontada (January 2013-January 2023), and COTA (January 2010-December 2022) databases. Patients (≥20 years) with advanced or metastatic EGFR exon20ins NSCLC who received amivantamab or mobocertinib following PBC were included. Patient characteristics and treatment patterns were analyzed descriptively. Time to next treatment or death (TTNTD) and time to discontinuation (TTD) were assessed using Kaplan-Meier estimates.
44 patients treated with amivantamab and 24 patients with mobocertinib after PBC met the selection criteria. Patient characteristics were consistent with previous studies. Most patients received amivantamab or mobocertinib as second-line (57 % and 50 %) or third-line (32 % and 33 %) therapy. The median TTNTD was 9.2 months for amivantamab and 4.2 months for mobocertinib. Fewer patients in the amivantamab cohort (43 %) experienced a TTNTD event than the mobocertinib cohort (63 %). The median TTD was 8.6 months for amivantamab and 2.3 months for mobocertinib, with a lower discontinuation rate in the amivantamab cohort (46 % vs 67 %).
Real-world patients with EGFR exon20ins NSCLC treated with amivantamab after PBC experienced median TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.
This retrospective study described patient characteristics, treatment patterns, and outcomes in patients with EGFR exon20ins-mutated advanced or metastatic NSCLC who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy. Real-world patients treated with amivantamab experienced TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial, while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.
描述表皮生长因子受体（EGFR）外显子20插入（exon20ins）阳性的晚期或转移性非小细胞肺癌（NSCLC）患者在接受铂类化疗（PBC）后接受阿美替尼单抗或莫博替尼单药治疗的特征、治疗模式及预后。
这项回顾性纵向队列研究汇总了Flatiron Health（2011年1月至2022年8月）、Ontada（2013年1月至2023年1月）和COTA（2010年1月至2022年12月）数据库中的电子健康记录。纳入年龄≥20岁、晚期或转移性EGFR exon20ins NSCLC且在PBC后接受阿美替尼单抗或莫博替尼治疗的患者。对患者特征和治疗模式进行描述性分析。采用Kaplan-Meier估计法评估下次治疗或死亡时间（TTNTD）和停药时间（TTD）。
44例PBC后接受阿美替尼单抗治疗的患者和24例接受莫博替尼治疗的患者符合入选标准。患者特征与既往研究一致。大多数患者接受阿美替尼单抗或莫博替尼作为二线治疗（分别为57%和50%）或三线治疗（分别为32%和33%）。阿美替尼单抗组的中位TTNTD为9.2个月，莫博替尼组为4.2个月。阿美替尼单抗组经历TTNTD事件的患者（43%）少于莫博替尼组（63%）。阿美替尼单抗组的中位TTD为8.6个月，莫博替尼组为2.3个月，阿美替尼单抗组的停药率较低（46%对67%）。
在现实世界中，PBC后接受阿美替尼单抗治疗的EGFR exon20ins NSCLC患者的中位TTNTD和TTD与注册试验中观察到的中位无进展生存期一致，而接受莫博替尼治疗的患者疾病进展更快，治疗停药频率更高。
这项回顾性研究描述了EGFR exon20ins突变的晚期或转移性NSCLC患者在接受铂类化疗后接受阿美替尼单抗或莫博替尼单药治疗的患者特征、治疗模式及预后。在现实世界中，接受阿美替尼单抗治疗的患者的TTNTD和TTD与注册试验中观察到的中位无进展生存期一致，而接受莫博替尼治疗的患者疾病进展更快，治疗停药频率更高。
